NCT07244757

Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control

Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control: A Randomized Controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 126 (estimated)
• Sponsor: Cairo University · Academic / Other
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

we aim to compare the analgesic efficacy of two intravenous ketorolac dosing regimens as part of a multimodal analgesic protocol that includes local wound infiltration for postoperative pain management after elective cesarean delivery.

Detailed description

Spinal anesthesia will be achieved by injecting 10 mg hyperbaric bupivacaine 0.5% plus 25 mcg fentanyl Prophylactic vasopressor will be administered in all patients, Following delivery, all patients will receive a single dose of dexamethasone (8 mg) along with the first dose of intravenous ketorolac. Subsequent ketorolac doses will be administered every 8 hours. After closing the fascia, the subcutaneous layer will be infiltrated with 30 mL of 0.25% bupivacaine. Postoperatively, if the Numeric rating scale is \> 3, intravenous nalbuphine 0.1 mg/kg titrated to response, with maximum single dose of 20 mg and maximum daily dose of 160 mg.

Conditions

• Postoperative Analgesia
• Cesarean Delivery
• Ketorolac

Interventions

Type	Name	Description
DRUG	Ketorolac 30 mg	administered intravenously as 30 mg diluted in 10 mL of normal saline and injected over more than 15 seconds
DRUG	Ketorolac 15mg	administered intravenously as either 15 mg diluted in 10 mL of normal saline and injected over more than 15 seconds.

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2025-11-24
• Last updated: 2026-01-13

Locations

1 site across 1 country: Egypt